Stay updated on Oraxol vs Taxol in Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Oraxol vs Taxol in Breast Cancer Clinical Trial page.

Latest updates to the Oraxol vs Taxol in Breast Cancer Clinical Trial page
- Check4 days agoChange DetectedThe page footer now identifies ClinicalTrials.gov as revision v3.8.1 instead of v3.8.0. The study information is unchanged.SummaryDifference0.0%

- Check11 days agoChange DetectedThe page now displays the completed Phase 3 Oraxol-versus-IV-paclitaxel study record for metastatic breast cancer, with its study plan, participant criteria, outcomes, locations, and record history.SummaryDifference61%

- Check18 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.8.0 instead of v3.7.2; the page still shows a 403 Forbidden error.SummaryDifference0.2%

- Check32 days agoChange DetectedA site-wide NIH notice about terminology during a website transition was added, and the site revision label changed from v3.7.1 to v3.7.2.SummaryDifference1%

- Check46 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1 while the page continued to display a 403 error.SummaryDifference0.2%

- Check60 days agoChange DetectedThe study page for NCT02594371 now shows a 403 Forbidden error instead of the study details. The error screen includes a Home link, indicating access to the page is blocked.SummaryDifference17%

Stay in the know with updates to Oraxol vs Taxol in Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Oraxol vs Taxol in Breast Cancer Clinical Trial page.